AstraZeneca Pharma India Limited has informed the Exchange about Shareholders meeting
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India held its 46th AGM on August 14, 2025 via video conferencing, where all six resolutions were passed with the requisite majority. Shareholders approved the financial statements for FY ended March 31, 2025, and declared a dividend of Rs. 32 per equity share for FY 2024-25. Ms. Hooi Bien Chuah was re-appointed as a director (retiring by rotation) with 99.94% approval, while Mr. Praveen Rao Akkinepally was appointed as Director and Managing Director with 99.90% approval. Messrs. Makarand M Joshi & Co. were appointed as Secretarial Auditors and the remuneration of Cost Auditors was ratified. Approval levels were overwhelmingly in favour across all resolutions, with over 2.10 crore valid votes cast.
The Rs. 32 per share dividend is a positive cash return for shareholders, while the appointment of a new Managing Director signals a leadership transition. The near-unanimous approval on all resolutions reflects strong shareholder confidence in the company's governance.